ArticleScientific reports2020
The prognostic and predictive potential of Ki-67 in triple-negative breast cancer.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 1 synthesis or guideline pooled it, 180 citations in OpenAlex.
- Association between ESR1 polymorphisms (XbaI & PvuII) and breast cancer risk: a comprehensive meta-analysis of case-control studies.Breast cancer research and treatment · 2025Pooled it
- Article
- Discrimination of Triple-Negative Breast Cancer: A Robust Clinical Baseline versus Multimodal Magnetic Resonance Imaging Integrated Models with Assessment of Generalizability.Breast cancer (Dove Medical Press) · 2026Article
- Seven Shades of Triple Negativity: A Review Unveiling the Low-Grade Spectrum of Breast Cancer.Cancers · 2025Review
- Ki-67 expression stratifies PD-L1-high NSCLC for immune checkpoint inhibitor plus chemotherapy: a real-world biomarker validation.Cancer immunology, immunotherapy : CII · 2025Article
- Correlation of Peripheral Neutrophil-to-Lymphocyte Ratio (NLR) with Ki-67 and Other Clinicopathological Parameters of Breast Carcinoma.Indian journal of surgical oncology · 2025Article
- Identification and prognostic significance of Ki-67-related genes in triple negative breast cancer.Discover oncology · 2025Article
- A Dual-Purpose Approach for an Anti-Emetic NK1R Antagonist as a Chemosensitizer and Cardioprotectant in a Preclinical Model of Triple-Negative Breast Cancer.International journal of molecular sciences · 2025Article
- Microbial community profiles in breast cancer and normal adjacent tissues: associations with clinicopathological characteristics.Translational cancer research · 2025Article
- Correlations of phosphorylated Nrf2 with responses to neoadjuvant chemotherapy in patients with triple-negative breast cancer.BMC women's health · 2025Observational
- Ki-67-Playing a key role in breast cancer but difficult to apply precisely in the real world.BMC cancer · 2025Article
- Tolerance of Adjuvant Ultrahypofractionated Whole-Breast Radiation Therapy Employing Moderately Hypofractionated Sequential Boost: A Single Institution Analysis.Advances in radiation oncology · 2025Article
- The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study.Breast cancer research and treatment · 2025Article
- Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node-Positive Breast Cancer: Real World Data.Thoracic cancer · 2025Article
- Multi-center study: ultrasound-based deep learning features for predicting Ki-67 expression in breast cancer.Scientific reports · 2025Article
- The association between Ki-67 expression and survival in breast cancer subtypes: a cross-sectional study of Ki-67 cut-point in northern Thailand.BMC cancer · 2025Article
- Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial-Mesenchymal Transition.Cancers · 2025Review
- Targeting low-risk triple-negative breast cancer: a review on de-escalation strategies for a new era.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Review
- Ultrasound-based radiomics for the evaluation of breast cancer.Frontiers in oncology · 2025Review
- Defining the optimal Ki67 cutoff values for survival prediction in neoadjuvant chemotherapy-treated patients with breast cancer.Frontiers in surgery · 2025Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a cell proliferation biomarker, Ki-67 is principally used in ER+/HER2- breast cancer. However, the importance and the best cutoff point of Ki-67 in triple-negative breast cancer (TNBC) remains unclear and was evaluated in this study.A total of 1800 patients with early invasive TNBC between 2011 and 2016 at Fudan University Shanghai Cancer Center were consecutively recruited for this study. The optimal cutoff for Ki-67 was assessed by Cutoff Finder. Propensity score matching (PSM, ratio = 1:2) was performed to match the Ki-67
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.